TrialCardiovascular diabetology2019

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.

Michael A Nauck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.